Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics--Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX

Rhea-AI Summary

Regen Therapy (NASDAQ:LTH) announced on April 9, 2026 a strategic partnership with Stealth Health to deploy white-label telemedicine, prescriber services, and pharmacy fulfillment across >3,000 clinics and 24,000 practitioners. Regen also signed an exclusive MOU with ZEO ScientifiX for biologic R&D and supply and will integrate Metabolic Code® analytics into its platform.

The collaborations aim to create a vertically integrated longevity and regenerative-care ecosystem combining clinical delivery, telemedicine infrastructure, and cGMP biologics development.

Positive

• Network scale: Access to >3,000 clinics and 24,000 practitioners
• Exclusive biologics MOU: ZEO positioned as core biologics partner
• Turnkey telemedicine: Stealth Health provides prescriber, pharmacy, fulfillment
• Data-driven care: Integration with Metabolic Code's 40,000-point Bayesian model

Negative

• ZEO relationship is an MOU, not a binding long-term supply contract
• Operational reliance on third-party prescriber and fulfillment networks

News Market Reaction – LTH

-1.72%

-1.72% Session close to close

In the Apr 9 session, LTH declined 1.72%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an expanded longevity and regenerative ecosystem linking Regen’s 3,000-...

Analysis

This announcement highlights an expanded longevity and regenerative ecosystem linking Regen’s 3,000-clinic network, Stealth Health’s prescriber and pharmacy infrastructure, and Metabolic Code’s 40,000-point analytics engine. For LTH, already cited in the release, it reinforces a strategic tilt toward personalized, data-driven health offerings. Investors may watch how quickly clinics adopt telemedicine workflows and biologic-driven programs, and whether this translates into measurable member engagement and ancillary revenue over time.

Key Figures

Clinic network size: 3,000 clinics Practitioner network: 24,000 practitioners Bayesian model size: 40,000-point model +2 more

5 metrics

Clinic network size 3,000 clinics Regen Therapy network coverage in the U.S.

Practitioner network 24,000 practitioners Regen Therapy practitioner footprint

Bayesian model size 40,000-point model Metabolic Code precision health engine

Physiological networks 5 networks TRIADS identified by Metabolic Code

Longevity market size $93 billion Projected global longevity market by 2027

Previous Partnership Reports

2 past events · Latest: Oct 08 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Oct 08	Branded gear partnership	Positive	-0.5%	Aion weighted vests named official partner across multiple Life Time programs.
May 07	Apparel partnership	Positive	+2.1%	lululemon named official apparel partner for Life Time racquet sports.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past partnership announcements have produced small, mixed reactions, with one slight gain and one slight decline the next day.

Recent Company History

Within the past year, LTH announced two branded partnerships: one with Aion weighted vests on Oct 8, 2025 and another with lululemon on May 7, 2024. These deals focused on enhancing member experience through equipment and apparel integration across Life Time’s ecosystem. Next-day moves around those releases were modest (between about -1% and +3%), framing today’s Regen/Stealth/ZEO collaboration as another ecosystem-expansion step rather than a transformational break.

Key Terms

telemedicine, glp-1, cGMP-compliant, extracellular vesicle biology, +4 more

8 terms

telemedicine technical

"white-label telemedicine platform embedded directly into clinical practice"

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

glp-1 medical

"GLP-1 weight management programs, therapeutic peptides, and broader longevity protocols"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

cGMP-compliant regulatory

"ZEO ensures consistent, high-quality biologic product availability through cGMP-compliant processes"

cGMP-compliant means a manufacturer follows the current Good Manufacturing Practices required by regulators to ensure products are made safely, consistently and with documented quality controls. For investors, cGMP compliance is like a certified clean kitchen and recipe book for a company’s manufacturing: it reduces the risk of product contamination, regulatory sanctions or recalls, supports reliable supply and can be essential for getting and keeping market approvals.

extracellular vesicle biology medical

"ZEO's expertise in extracellular vesicle biology, perinatal-derived therapeutics"

The study of how cells send and receive tiny packets of biological material—like proteins and genetic instructions—through small membrane-bound bubbles. Think of these packets as cellular text messages or delivery boxes that can change behavior in other cells. Investors care because this biology underpins new ways to diagnose disease, deliver drugs, or create therapies; advances can create commercial products, regulatory pathways, partnerships, and risks that influence company value.

perinatal-derived therapeutics medical

"extracellular vesicle biology, perinatal-derived therapeutics, and acellular signaling technologies"

Perinatal-derived therapeutics are medical products made from tissues or cells obtained around the time of birth—such as the placenta, umbilical cord, or amniotic fluid—used to treat disease or help tissues heal. For investors, they matter because they represent a growing category of regenerative and biologic therapies with unique sourcing, manufacturing, regulatory and ethical considerations; like turning a byproduct of birth into precision repair tools, they can offer new markets but also carry science, supply and approval risks.

acellular signaling technologies medical

"perinatal-derived therapeutics, and acellular signaling technologies will support the development"

Acellular signaling technologies are therapies or products that deliver biological messages—such as proteins, small molecules, or extracellular vesicles—without transplanting living cells, using those signals to trigger repair, immune responses or other biological changes. For investors, they matter because they can offer simpler manufacturing, lower safety risks and clearer regulatory paths than cell therapies, potentially enabling faster scale-up and wider market adoption, much like using a targeted instruction manual instead of hiring a whole new team.

hormone replacement therapy medical

"compounded medications, hormone replacement therapy, GLP-1 weight management programs"

Hormone replacement therapy is a medical treatment that supplies the body with hormones it no longer makes enough of, like adding oil to an engine to restore smooth function. Investors care because demand, safety concerns, regulation, patents and pricing for these medicines and related devices can materially affect the revenues, costs and growth prospects of drugmakers, clinics and healthcare suppliers involved in producing or delivering them.

bayesian model technical

"Utilizing a proprietary 40,000-point Bayesian model, the platform delivers individualized"

A Bayesian model is a statistical method that starts with an initial belief about an unknown quantity and updates that belief as new data arrive, much like changing an opinion when shown new evidence. For investors, it matters because it produces clearer probability-based forecasts and explicit measures of uncertainty, helping to combine different information sources, adjust predictions as markets change, and make better-informed risk and allocation decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem—featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code^®-driven longevity programs and ZEO ScientifiX's advanced biologic offerings—delivered through a white-label telemedicine platform embedded directly into clinical practice.

DALLAS, April 9, 2026 /PRNewswire/ - Regen Therapy has entered into a strategic partnership with Stealth Health to bring scalable, white-label telemedicine and longevity services to its network of more than 3,000 clinics and 24,000 practitioners across the U.S. In parallel, Regen Therapy has entered into a memorandum of understanding ('MOU") with ZEO ScientifiX, for the establishment of an exclusive scientific and biologics strategic collaboration, pursuant to which ZEO is positioned as the core supplier of advanced biologic therapeutics underpinning the next-generation of regenerative product offerings on Regen's platform.

Together, these collaborations create a vertically integrated ecosystem—combining clinical delivery, telemedicine infrastructure, and scientifically advanced biologic product development—to enable clinics to deliver comprehensive, data-driven longevity and regenerative care at scale.

The collaboration with Stealth Health will enable participating clinics to integrate a licensed prescriber network, pharmacy fulfillment infrastructure, and telemedicine platform directly into their existing operations—allowing them to offer physician-guided consultations, compounded medications, hormone replacement therapy, GLP-1 weight management programs, therapeutic peptides, and broader longevity protocols without building in-house capabilities.

"Regen Therapy has built one of the most clinically credible networks in regenerative medicine, and the clinics in their ecosystem are hungry for ways to serve their patients better," said Matthew Mazzuca, CEO and Co-Founder of Stealth Health. "Our platform gives those clinics instant access to our prescriber network, our pharmacy fulfillment infrastructure, and a full menu of longevity-focused services their patients are already asking for—all delivered under the clinic's own brand. This is how longevity medicine scales: by empowering the clinics that are already on the front lines."

Complementing this infrastructure, the MOU contemplates that ZEO ScientifiX will serve as Regen Therapy's exclusive partner for biologic research, development, and manufacturing of biologic therapeutics to be incorporated into Regen's platform. ZEO's expertise in extracellular vesicle biology, perinatal-derived therapeutics, and acellular signaling technologies will support the development and supply of advanced regenerative products incorporated into Regen's expanding clinical platform. This relationship reflects Regen's commitment to scientific rigor, product innovation, and scalable clinical outcomes.

"For ZEO ScientifiX, the strategic collaboration represents both validation of its commitment to research and product development and an opportunity to play a central role in a rapidly expanding clinical network expected to be a major force in the U.S. regenerative medicine market." said Ian Bothwell, Chief Executive Officer of ZEO ScientifiX. "By aligning with Regen Therapy's platform, we believe ZEO's innovative therapeutics can be translated more efficiently into real-world clinical applications."

Positioned as an extension of brick-and-mortar care, the model allows clinics to expand into high-demand, specialized services while Stealth Health manages clinical oversight, prescription workflows, and fulfillment, and ZEO ensures consistent, high-quality biologic product availability through cGMP-compliant processes. The turnkey approach removes regulatory and operational barriers while introducing a new level of scientific depth to clinical offerings.

Central to the platform is integration with the Metabolic Code^® system, a precision health platform founded by James LaValle, RPh, CCN. Utilizing a proprietary 40,000-point Bayesian model, the platform delivers individualized health assessments and care plans by identifying imbalances across five key physiological networks, known as TRIADS™. The system, already adopted by organizations including LIFE TIME (NYSE: LTH), enables clinics to introduce data-driven longevity programming as part of a fully managed patient experience.

"The future of longevity medicine is personalized, data-driven, and accessible—and it starts inside the clinic," said James LaValle, clinical pharmacist, Founder of Metabolic Code^®, Co-Chair of the American Academy of Anti-Aging Medicine, Chair of the International Peptide Society, and Chief Science Officer at LIFE TIME. "When you combi ne the clinical depth of Metabolic Code's assessment platform with Regen Therapy's clinic network and Stealth Health's prescriber infrastructure, you give practitioners the ability to deliver precision longevity care to their patients at a scale that hasn't been possible until now."

"What we are seeking to build is not a single therapy, but a new clinical architecture for how regenerative medicine is delivered," said George C. Shapiro, MD, FACC, Chief Medical Officer of ZEO ScientifiX. "By integrating biologic engineering, cGMP manufacturing, and data-driven clinical deployment, this strategic collaboration provides the potential to establish the foundation for a scalable system—one capable of ultimately standardizing outcomes across a national network and fundamentally advancing how we treat aging, inflammation, and cellular dysfunction."

"This is not just a partnership, it's the creation of an integrated ecosystem designed to define the future of longevity and regenerative health," Sanjiv Lal, partner at Regen Therapy.

The partnership comes as demand for proactive, personalized health solutions continues to accelerate, with the global longevity market projected to exceed $93 billion by 2027. Despite this growth, many clinics remain limited by lack of access to specialized prescribers, pharmacy networks, and integrated technology. By combining Regen Therapy's clinical network and education platform with Stealth Health's infrastructure and Metabolic Code's analytics engine, the partnership creates a scalable pathway for providers to expand offerings, drive new revenue, and meet evolving patient expectations.

About Regen Therapy

Regen Therapy is a clinical education and consulting platform for healthcare providers and longevity clinics. Co-founded by Dr. Arvind Chakravarthy, MD, MBA, and Sanjiv Lal, Regen Therapy provides research insights, clinical education, fractional longevity advisory services, and operational support to help medical practices implement regenerative medicine programs responsibly and at scale. With partnerships spanning organizations including Hall of Fame Health and a growing network of over 3,000 clinics, Regen Therapy is defining the future of regenerative science.

About Stealth Health 

Stealth Health is a telemedicine and longevity medicine company headquartered in Texas. The company provides a white-label MSO platform for clinic partners, a licensed prescriber network, direct-to-patient telehealth services, and pharmacy fulfillment coordination—all built on a HIPAA-compliant technology stack. Stealth Health's platform enables brick-and-mortar clinics to offer their patients specialized medications, hormone therapies, peptides, and longevity programs under the clinic's own brand.

About ZEO ScientifiX 

ZEO ScientifiX is a clinical-stage biopharmaceutical company specializing in the development and cGMP-compliant manufacturing of advanced biologic therapeutics. The company is focused on advancing regenerative medicine through scientific innovation, rigorous research, and scalable product development, supporting next-generation therapies in longevity and human performance.

About Metabolic Code^® 

Metabolic Code® is a cloud-based precision health platform founded by Jim LaValle, RPh, CCN, that uses a proprietary 40,000-point Bayesian Model algorithm to deliver personalized health assessments, targeted care plans, and ongoing metabolic optimization.

Forward-Looking Statements Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although Regen Therapy, Zeo Scientifix, Stealth Health and Metabolic Code all believe that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. Regen Therapy, Zeo Scientifix, Stealth Health and Metabolic Code have no intention and specifically disclaims any duty to update the information in this press release.

Metabolic Code
TeamLaVallePR@HillTop-Ent.com 
TeamLaVallePR@BehrmanCesa.com

Zeo Scientifix, Inc.
Zeo Scientifix – ir@zeoscientifix.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regen-therapy-partners-with-stealth-health-to-bring-specialized-telemedicine-services-and-longevity-programs-to-3-000-clinicspowered-by-an-exclusive-scientific-and-biologics-strategic-collaboration-with-zeo-scientifix-302737427.html

SOURCE Stealth Health

FAQ

What did Regen Therapy (LTH) announce on April 9, 2026 about clinic services?

They announced a partnership to offer white-label telemedicine and longevity services to clinics. According to Regen Therapy, the program embeds Stealth Health's prescriber network, pharmacy fulfillment, and longevity protocols directly into participating clinics' operations for turnkey delivery.

How many clinics and practitioners will Regen Therapy's LTH partnership reach?

The collaboration targets more than 3,000 clinics and 24,000 practitioners. According to Regen Therapy, that network will be able to offer integrated telemedicine, compounded medications, HRT, GLP-1 programs, and peptide therapies.

What does the MOU between Regen Therapy (LTH) and ZEO ScientifiX mean for biologics supply?

The MOU positions ZEO as Regen's exclusive partner for biologic R&D and manufacturing. According to Regen Therapy, ZEO will support extracellular vesicle and perinatal-derived therapeutics to supply cGMP biologic products for the platform.

How does Metabolic Code integrate with Regen Therapy's LTH platform?

Metabolic Code will provide precision health analytics and individualized care plans via a 40,000-point Bayesian model. According to Regen Therapy, clinics will use Metabolic Code TRIADS™ assessments to deliver data-driven longevity protocols.

What operational risks should investors consider for Regen Therapy (LTH)?

Key risks include dependency on third-party partners and the nonbinding nature of the ZEO MOU. According to Regen Therapy, the model relies on Stealth Health and ZEO to manage clinical oversight, fulfillment, and biologic supply consistency.